Development of a New De Novo Design Algorithm for Exploring Chemical Space

2014 ◽  
pp. n/a-n/a ◽  
Author(s):  
Kazuaki Mishima ◽  
Hiromasa Kaneko ◽  
Kimito Funatsu
Keyword(s):  
De Novo ◽  
Chemical Space ◽  
De Novo Design ◽  
Design Algorithm

scholarly journals AutoDesigner, a De Novo Design Algorithm for Rapidly Exploring Large Chemical Space for Lead Optimization: Application to the Design and Synthesis of D-Amino Acid Oxidase Inhibitors

2021 ◽  
Author(s):  
Pieter H Bos ◽  
Evelyne M. Houang ◽  
Fabio Ranalli ◽  
Abba E. Leffler ◽  
Nicholas A. Boyles ◽  
...  
Keyword(s):  
Amino Acid ◽  
Drug Discovery ◽  
De Novo ◽  
Chemical Space ◽  
De Novo Design ◽  
Lead Optimization ◽  
Acid Oxidase ◽  
Amino Acid Oxidase ◽  
Design Algorithm ◽  
Starting Point

The lead optimization stage of a drug discovery program generally involves the design, synthesis and assaying of hundreds to thousands of compounds. The design phase is usually carried out via traditional medicinal chemistry approaches and/or structure based drug design (SBDD) when suitable structural information is available. Two of the major limitations of this approach are (1) difficulty in rapidly designing potent molecules that adhere to myriad project criteria, or the multiparameter optimization (MPO) problem, and (2) the relatively small number of molecules explored compared to the vast size of chemical space. To address these limitations we have developed AutoDesigner, a de novo design algorithm. AutoDesigner employs a cloud-native, multi-stage search algorithm to carry out successive rounds of chemical space exploration and filtering. Millions to billions of virtual molecules are explored and optimized while adhering to a customizable set of project criteria such as physicochemical properties and potency. Additionally, the algorithm only requires a single ligand with measurable affinity and a putative binding model as a starting point, making it amenable to the early stages of a SBDD project where limited data is available. To assess the effectiveness of AutoDesigner, we applied it to the design of novel inhibitors of D-amino acid oxidase (DAO), a target for the treatment of schizophrenia. AutoDesigner was able to generate and efficiently explore over 1 billion molecules to successfully address a variety of project goals. The compounds generated by AutoDesigner that were synthesized and assayed (1) simultaneously met not only physicochemical criteria, clearance and central nervous system (CNS) penetration (Kp,uu) cutoffs, but also potency thresholds; (2) fully utilize structural data to discover and explore novel interactions and a previously unexplored subpocket in the DAO active site. The reported data demonstrate that AutoDesigner can play a key role in accelerating the discovery of novel, potent chemical matter within the constraints of a given drug discovery lead optimization campaign.

Chemical-Space-Based de Novo Design Method To Generate Drug-Like Molecules

2016 ◽  
Vol 56 (10) ◽  
pp. 1885-1893 ◽  
Author(s):  
Shunichi Takeda ◽  
Hiromasa Kaneko ◽  
Kimito Funatsu
Keyword(s):  
De Novo ◽  
Chemical Space ◽  
Design Method ◽  
De Novo Design

scholarly journals De Novo Design of New Chemical Entities (NCEs) for SARS-CoV-2 Using Artificial Intelligence

2020 ◽  
Author(s):  
Navneet Bung ◽  
Sowmya Ramaswamy Krishnan ◽  
Gopalakrishnan Bulusu ◽  
Arijit Roy
Keyword(s):  
Artificial Intelligence ◽  
Small Molecules ◽  
De Novo ◽  
Chemical Space ◽  
De Novo Design ◽  
Protein Targets ◽  
Post Translational Modifications ◽  
Global Pandemic ◽  
New Chemical Entities ◽  
3Cl Protease

The novel SARS-CoV-2 is the source of a global pandemic COVID-19, which has severely affected the health and economy of several countries. Multiple studies are in progress, employing diverse approaches to design novel therapeutics against the potential target proteins in SARS-CoV-2. One of the well-studied protein targets for coronaviruses is the chymotrypsin-like (3CL) protease, responsible for post-translational modifications of viral polyproteins essential for its survival and replication in the host. There are ongoing attempts to repurpose the existing viral protease inhibitors against 3CL protease of SARS-CoV-2. Recent studies have proven the efficiency of artificial intelligence techniques in learning the known chemical space and generating novel small molecules. In this study, we employed deep neural network-based generative and predictive models for de novo design of new small molecules capable of inhibiting the 3CL protease. The generated small molecules were filtered and screened against the binding site of the 3CL protease structure of SARS-CoV-2. Based on the screening results and further analysis, we have identified 31 potential compounds as ideal candidates for further synthesis and testing against SARS-CoV-2. The generated small molecules were also compared with available natural products. Two of the generated small molecules showed high similarity to a plant natural product, Aurantiamide, which can be used for rapid testing during this time of crisis.

scholarly journals De Novo Design of New Chemical Entities (NCEs) for SARS-CoV-2 Using Artificial Intelligence

2020 ◽  
Author(s):  
Navneet Bung ◽  
Sowmya Ramaswamy Krishnan ◽  
Gopalakrishnan Bulusu ◽  
Arijit Roy
Keyword(s):  
Artificial Intelligence ◽  
Small Molecules ◽  
De Novo ◽  
Chemical Space ◽  
De Novo Design ◽  
Protein Targets ◽  
Post Translational Modifications ◽  
Global Pandemic ◽  
New Chemical Entities ◽  
3Cl Protease

The novel SARS-CoV-2 is the source of a global pandemic COVID-19, which has severely affected the health and economy of several countries. Multiple studies are in progress, employing diverse approaches to design novel therapeutics against the potential target proteins in SARS-CoV-2. One of the well-studied protein targets for coronaviruses is the chymotrypsin-like (3CL) protease, responsible for post-translational modifications of viral polyproteins essential for its survival and replication in the host. There are ongoing attempts to repurpose the existing viral protease inhibitors against 3CL protease of SARS-CoV-2. Recent studies have proven the efficiency of artificial intelligence techniques in learning the known chemical space and generating novel small molecules. In this study, we employed deep neural network-based generative and predictive models for de novo design of new small molecules capable of inhibiting the 3CL protease. The generated small molecules were filtered and screened against the binding site of the 3CL protease structure of SARS-CoV-2. Based on the screening results and further analysis, we have identified 31 potential compounds as ideal candidates for further synthesis and testing against SARS-CoV-2. The generated small molecules were also compared with available natural products. Two of the generated small molecules showed high similarity to a plant natural product, Aurantiamide, which can be used for rapid testing during this time of crisis.

scholarly journals REINVENT 2.0 – an AI Tool for De Novo Drug Design

2020 ◽  
Author(s):  
Thomas Blaschke ◽  
Josep Arús-Pous ◽  
Hongming Chen ◽  
Christian Margreitter ◽  
Christian Tyrchan ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Drug Design ◽  
De Novo ◽  
Chemical Space ◽  
De Novo Design ◽  
Interaction Point ◽  
De Novo Drug Design ◽  
Generative Methods ◽  
Collaborative Efforts ◽  
Scientific Collaborations

With this application note we aim to offer the community a production-ready tool for de novo design. It can be effectively applied on drug discovery projects that are striving to resolve either exploration or exploitation problems while navigating the chemical space. By releasing the code we are aiming to facilitate the research on using generative methods on drug discovery problems and to promote the collaborative efforts in this area so that it can be used as an interaction point for future scientific collaborations.

scholarly journals REINVENT 2.0 – an AI Tool for De Novo Drug Design

2020 ◽  
Author(s):  
Thomas Blaschke ◽  
Josep Arús-Pous ◽  
Hongming Chen ◽  
Christian Margreitter ◽  
Christian Tyrchan ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Drug Design ◽  
De Novo ◽  
Chemical Space ◽  
De Novo Design ◽  
Interaction Point ◽  
De Novo Drug Design ◽  
Generative Methods ◽  
Collaborative Efforts ◽  
Scientific Collaborations

With this application note we aim to offer the community a production-ready tool for de novo design. It can be effectively applied on drug discovery projects that are striving to resolve either exploration or exploitation problems while navigating the chemical space. By releasing the code we are aiming to facilitate the research on using generative methods on drug discovery problems and to promote the collaborative efforts in this area so that it can be used as an interaction point for future scientific collaborations.

scholarly journals EAI-TupletScore, a pharmacophore and shape driven ligand-based de-novo design algorithm

2009 ◽  
Vol 3 (S1) ◽  
Author(s):  
KM Smith ◽  
BB Masek ◽  
RD Clark ◽  
T Mansley ◽  
E Abrahamian ◽  
...  
Keyword(s):  
De Novo ◽  
De Novo Design ◽  
Design Algorithm

scholarly journals De Novo Design of New Chemical Entities (NCEs) for SARS-CoV-2 Using Artificial Intelligence

2020 ◽  
Author(s):  
Navneet Bung ◽  
Sowmya Ramaswamy Krishnan ◽  
Gopalakrishnan Bulusu ◽  
Arijit Roy
Keyword(s):  
Artificial Intelligence ◽  
Small Molecules ◽  
De Novo ◽  
Chemical Space ◽  
De Novo Design ◽  
Protein Targets ◽  
Post Translational Modifications ◽  
Global Pandemic ◽  
New Chemical Entities ◽  
3Cl Protease

The novel SARS-CoV-2 is the source of a global pandemic COVID-19, which has severely affected the health and economy of several countries. Multiple studies are in progress, employing diverse approaches to design novel therapeutics against the potential target proteins in SARS-CoV-2. One of the well-studied protein targets for coronaviruses is the chymotrypsin-like (3CL) protease, responsible for post-translational modifications of viral<br>polyproteins essential for its survival and replication in the host. There are ongoing attempts to repurpose the existing viral protease inhibitors against 3CL protease of SARS-<br>CoV-2. Recent studies have proven the efficiency of artificial intelligence techniques in learning the known chemical space and generating novel small molecules. In this study,<br>we employed deep neural network-based generative and predictive models for de novo design of new small molecules capable of inhibiting the 3CL protease. The generated<br>small molecules were filtered and screened against the binding site of the 3CL protease structure of SARS-CoV-2. Based on the screening results and further analysis, we have<br>identified 31 potential compounds as ideal candidates for further synthesis and testing against SARS-CoV-2.

scholarly journals De novo design of new chemical entities for SARS-CoV-2 using artificial intelligence

2021 ◽  
Author(s):  
Navneet Bung ◽  
Sowmya R Krishnan ◽  
Gopalakrishnan Bulusu ◽  
Arijit Roy
Keyword(s):  
Small Molecules ◽  
Predictive Models ◽  
Deep Neural Network ◽  
De Novo ◽  
Chemical Space ◽  
De Novo Design ◽  
The Novel ◽  
New Chemical Entities ◽  
Novel Coronavirus ◽  
3Cl Protease

Background: The novel coronavirus SARS-CoV-2 has severely affected the health and economy of several countries. Multiple studies are in progress to design novel therapeutics against the potential target proteins in SARS-CoV-2, including 3CL protease, an essential protein for virus replication. Materials & methods: In this study we employed deep neural network-based generative and predictive models for de novo design of small molecules capable of inhibiting the 3CL protease. The generative model was optimized using transfer learning and reinforcement learning to focus around the chemical space corresponding to the protease inhibitors. Multiple physicochemical property filters and virtual screening score were used for the final screening. Conclusion: We have identified 33 potential compounds as ideal candidates for further synthesis and testing against SARS-CoV-2.

scholarly journals Towards the de Novo Design of HIV-1 Protease Inhibitors Based on Natural Products

2021 ◽  
Author(s):  
Ana L. Chávez-Hernández ◽  
K. Eurídice Juárez-Mercado ◽  
Fernanda I. Saldívar-González ◽  
José L. Medina-Franco
Keyword(s):  
Natural Products ◽  
Natural Product ◽  
Protease Inhibitors ◽  
De Novo ◽  
Chemical Space ◽  
Public Health Problem ◽  
Building Blocks ◽  
De Novo Design ◽  
Viral Protease ◽  
Hiv 1

The acquired immunodeficiency syndrome (AIDS) caused by the human immunodeficiency virus (HIV) continues to be a public health problem. In 2020, 680,000 people died from HIV-related causes, and 1.5 million people were infected. Antiretrovirals are only a way to control HIV infection but not to cure AIDS. As such, effective treatment must be developed to control AIDS. Developing a drug is not an easy task, and there is an enormous amount of work and economic resources invested. For this reason, it is highly convenient to employ computer-aided drug design methods, which can help generate and identify novel molecules. Using the de novo design, new novel molecules can be developed using fragments as building blocks. In this work, we develop a virtual-focused compound library of HIV-1 viral protease inhibitors from natural product fragments. Natural products are characterized by a large diversity of functional groups, many sp3 atoms, and chiral centers. Pseudo-natural products are a combination of natural products fragments that keep the desired structural characteristics from different natural products. An interactive version of chemical space visualization of virtual compounds focused on HIV-1 viral protease inhibitors from natural product fragments is freely available at https://figshare.com/s/ceb58d58e8f5585ce67e.

Sign in / Sign up

Export Citation Format

Share Document